Market Research Logo

KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Pipeline Review, H1 2016

KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Pipeline Review, H1 2016’, provides in depth analysis on KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) targeted pipeline therapeutics.

The report provides comprehensive information on the KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54)
  • The report reviews KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) targeted therapeutics and enlists all their major and minor projects
  • The report assesses KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) Overview
Therapeutics Development
KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Products under Development by Stage of Development
KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Products under Development by Therapy Area
KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Products under Development by Indication
KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Pipeline Products Glance
Late Stage Products
Early Stage Products
KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Products under Development by Companies
KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Products under Development by Universities/Institutes
KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Companies Involved in Therapeutics Development
Crinetics Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Drug Profiles
Kisspeptin-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
kisspeptin-54 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-448 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Discontinued Products
KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Featured News & Press Releases
Jan 28, 2015: Crinetics Pharmaceuticals Awarded $1.5MM NIH Phase-II SBIR Grant to Develop Kisspeptin Receptor Antagonists for PCOS and Other Women’s Health Diseases
Jun 18, 2013: Kisspeptin hormone could make IVF safer for mothers
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by Crinetics Pharmaceuticals, Inc., H1 2016
Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
Discontinued Products, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report